Xenbase Image ID: 23797

Fig. 8. Antisense morpholinos against XHRT1 reduces the expression of glomus and proximal tubule markers. (A) Design of the XHRT1-MO that targets both pseudoalleles. (Bottom) In vivo translation of XHRT1a-eGFP is specifically inhibited by XHRT1-MOs. Embryos were injected with 500 pg of XHRT1-eGFP or eGFP mRNA, alone or in combination with 15 ng of the XHRT1-MO, as indicated. (B-O) Embryos injected with 15 ng XHRT1-MO and β-galactosidase mRNA analysed with the indicated markers. (B-I) Control and injected sides of XHRT1-MO-injected embryos with decreased XSMP-30, xPDZK1, xWT1 and nephrin expression. (J,K) Transversal sections of XHRT1-MO-injected embryos. (L,M) XHRT1 knockdown has no effect on Evi1 expression. (N,O) Transversal sections of XHRT1-MO-injected embryos. Ep. keratin and N-tubulin expression is unaffected by XHRT1 knockdown. (P) Co-injection of the XHRT1-MO with 500 pg of XHRT1a-mut-MT-hGR mRNA rescues XSMP-30 expression in stage 22 dexamethasone-treated XHRT1-MO-injected embryos. Changes in the expression of XSMP-30 were scored and classified as in Fig. 6A. (Q) Co-injection of 15 ng XHRT1-MO inhibits the effect of overexpression of hGR/Su(H)/Ank (500 pg) on XSMP-30 expression. Injected embryos were dexamethasone treated at stage 22. Changes in the expression of XSMP-30 were classified into two groups (no change or increase, decrease). n, number of embryos analysed; m, medial intermediate mesodermal layer; pn, pronephros; pt, pronephric tubules. Image published in: Taelman V et al. (2006) Copyright © 2006. Image reproduced with permission of the publisher and the copyright holder. This is an Open Access article distributed under the terms of the Creative Commons Attribution License. Larger Image Printer Friendly View

Return to previous page